FDA Black Box Warning for Pfizer Smoking Cessation Drug Chantix(R); Cory Watson Crowder and DeGaris Charges Pfizer Knew of Potential Chantix Dangers

Wed. July 01, 2009; Posted: 07:40 PM

BIRMINGHAM, AL, Jul 01, 2009 (MARKETWIRE via COMTEX) -- PFE | Quote | Chart | News | PowerRating -- The FDA has mandated a "Black Box Warning" requiring Pfizer Inc., manufacturer of Chantix(R), to strengthen warnings about the health risks and dangers associated with using the drug. Chantix(R) (varenicline) is advertised as an aid to help people quit smoking. The order for a Boxed Warning comes on the heels of reports linking Chantix(R) to serious injuries and death. FDA officials noted, "These reports included those with a temporal relationship between the use of [Chantix] and suicidal events and the occurrence of suicidal ideation and suicidal behavior in patients with no history of psychiatric disease." In addition to requiring a stronger Boxed Warning, the FDA is requiring Pfizer to "develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms." The FDA Advisory also requires new "Black Box" warnings to be included on packages of smoking cessation drug Zyban(R) (buproprion).

Attorney Kristian Rasmussen of Cory Watson Crowder and DeGaris in Birmingham, Alabama, filed the first lawsuits in the country on behalf of Chantix(R) victims. According to Rasmussen, "alarming evidence linking Chantix(R) to many severe injuries and death has continued to mount since Pfizer rushed the dangerous drug onto the market."

Rasmussen says Cory Watson Crowder and DeGaris has received more than 2,900 inquiries from consumers from across the country. Rasmussen said his firm currently represents more than 350 Chantix victims. Cory Watson Crowder & DeGaris is recognized nationally for its practice in mass torts litigation of defective medical devices and pharmaceuticals, class actions, multidistrict litigation and complex litigation including business and securities litigation and environmental litigation.

Media contact:
Melanie McCraney
Email Contact
(205) 910-1323

SOURCE: Cory Watson Crowder & DeGaris

http://www2.marketwire.com/mw/emailprcntct?id=5EEF61D72B785CB8

For full details on Pfizer Inc (PFE) click here. Pfizer Inc (PFE) has Short Term PowerRatings of 6. Details on Pfizer Inc (PFE) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.